<?xml version="1.0" encoding="UTF-8"?>
<p>In the context of oncolytic viruses, their selective replication triggers tumor cell death and vector spread into neighboring cells, providing an interesting approach for cancer therapy [
 <xref rid="B32-biomedicines-08-00060" ref-type="bibr">32</xref>]. Immunization studies in experimental models have employed a wide range of viral vectors based on adenoviruses, alphaviruses, herpes simplex viruses, coxsackie viruses and vaccinia viruses, targeting cancer types like glioblastoma, colon, cervix, and lung cancer as well as melanoma [
 <xref rid="B33-biomedicines-08-00060" ref-type="bibr">33</xref>,
 <xref rid="B34-biomedicines-08-00060" ref-type="bibr">34</xref>]. The first virus-based melanoma drug was approved by the FDA in 2015 [
 <xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>]. 
</p>
